Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Eur J Pharmacol. 2018 Sep 5;841:33–48. doi: 10.1016/j.ejphar.2018.08.040

Fig. 7. SsnB treatment decreases proliferation and induces apoptosis in hepatic stellate cells.

Fig. 7.

Fig. 7.

A. Cell cycle analysis of untreated cells (control), cells treated with LPS, LPS+SsnB10(10 μM), and LPS+SsnB100(100 μM). Quantitation of the PI staining data is presented as the cell cycle distribution percentages. B. Apoptosis is indicated by TUNEL based ApopTag® technology (EMD Millipore, MO) which labels 3’-OH ends of DNA fragments by fluorescent antibody as detected by immunofluorescence microscopy in Control (untreated), LPS-treated, and LPS+SsnB100 (100 μM) treated LX2 cells. C. Western blot analysis of p53, cleaved caspase3 (Casp3), total caspase3 (Casp3), cleaved PARP1 and β-actin protein levels of Control (untreated), LPS-treated, LPS+SsnB10 (10 μM), and LPS +SsnB100(100 μM) treated LX2 cells. D. Morphometric analysis of western blot where the bar diagram represents the level of p53, cleaved caspase3, total caspase3, cleaved PARP1 normalized against β-actin of respective samples. (*) P < 0.05 is considered statistically significant. E. TUNEL assay-based apoptosis analysis of Control, NASH, and NASH+SsnB treated mice liver samples. F. Morphometric analysis of apoptotic events/3 microscopic field. (*) P < 0.05 is considered statistically significant.